GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Senseonics Holdings
Senseonics produces an implantable sensor for continuous glucose monitoring. Its stock price is a story of struggle for share in the highly competitive diabetes treatment market. The chart reflects both the uniqueness of the technology and the challenges of commercialization.
Share prices of companies in the market segment - Therapeutic medical equipment
Senseonics Holdings develops and markets implantable continuous glucose monitoring (CGM) systems for people with diabetes, offering a long-term solution. We've classified it in the "Therapeutic Medical Equipment" segment. The chart below reflects the dynamics of this competitive sector, where innovations directly impact the quality of life of millions of patients.
Broad Market Index - GURU.Markets
Senseonics Holdings developed the Eversense implantable continuous glucose monitoring sensor, which lasts up to six months. As part of the GURU.Markets index, it represents the diabetes technology sector. The chart below represents the entire market. See how Senseonics shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SENS - Daily change in the company's share price Senseonics Holdings
Change_co for Senseonics, a manufacturer of implantable glucose monitoring systems, reflects volatility in the medical technology sector. Daily fluctuations indicate sensitivity to product and competitive news. This metric is important for analyzing innovative medical devices on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Therapeutic medical equipment
Senseonics Holdings, Inc. is a manufacturer of implantable glucose meters. This chart highlights the high volatility of the MedTech sector. Comparing it to SENS, which competes in a fast-growing market, helps us understand how its innovations are ahead of industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Senseonics is a manufacturer of an implantable sensor for continuous glucose monitoring. The diabetes medical device market is growing rapidly. The chart below shows the volatility in this sector, helping to assess how Senseonics shares are responding to innovation and competition.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Senseonics Holdings
Senseonics Holdings' year-over-year performance is a story of the battle for market share in continuous glucose monitoring systems. Its market capitalization over the past 12 months reflects its success in promoting its unique implantable Eversense sensor, which requires replacement only every six months, a key competitive advantage over market leaders.
Annual dynamics of market capitalization of the market segment - Therapeutic medical equipment
Senseonics Holdings, Inc. is developing an implantable sensor for continuous glucose monitoring. Its technology offers convenience for diabetes patients. The chart below shows how its battle for market share with leaders like DexCom and its path to profitability are impacting its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Senseonics, with its implantable glucose sensor, is a story of a battle for market share. Its stock price reflects not economic cycles, but its success in competing with giants like DexCom and Abbott. The chart is a volatile bet on whether its unique technology will find its way to patients.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Senseonics Holdings
The growth of Senseonics, a medical device manufacturer, depends on the adoption of its technology. The monthly fluctuations on the chart reflect the growth in the number of installations of its Eversense implantable glucose monitoring system, a key indicator of its operational success and market competition.
Monthly dynamics of market capitalization of the market segment - Therapeutic medical equipment
Senseonics Holdings, Inc. is a medical technology company that developed and commercializes the Eversense implantable continuous glucose monitoring (CGM) system. Its sector dynamics, shown in the graph, reflect the growth of the diabetes market. Against this backdrop, one can assess how its unique long-term system competes with more traditional wearable CGM devices.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Senseonics Holdings produces implantable glucose monitoring systems. Its stock price depends on the success of its commercialization and competition. The chart shows how the stock reacts to sales news and regulatory approvals, moving independently of the broader market and reflecting the specifics of the medical technology sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Senseonics Holdings
Senseonics Holdings produces an implantable continuous glucose monitoring (CGM) sensor for diabetics. Its weekly stock price reflects competition in the CGM market and its ability to gain market share through the convenience of its system.
Weekly dynamics of market capitalization of the market segment - Therapeutic medical equipment
Senseonics, like the entire diabetes device industry, responds weekly to industry-wide news on technological innovations and insurance coverage. This chart shows how the company is positioned within the context of this competitive medical segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Senseonics Holdings develops implantable glucose sensors. As a medical technology company, it should be less dependent on the economy. The chart will show how insulated its shares are from market fluctuations, moving in sync with product news and regulatory decisions.
Market capitalization of the company, segment and market as a whole
SENS - Market capitalization of the company Senseonics Holdings
Senseonics Holdings' market cap is a bet on a new generation of diabetes devices. The company's chart, which developed an implantable sensor for continuous glucose monitoring, demonstrates investors' confidence that the convenience and durability of its system will capture the market.
SENS - Share of the company's market capitalization Senseonics Holdings within the market segment - Therapeutic medical equipment
Senseonics Holdings is gaining market share in diabetes glucose monitoring with its unique, long-lasting implantable sensor, Eversense. Its market capitalization reflects both the innovative nature of its technology and the challenges of competing with market leaders.
Market capitalization of the market segment - Therapeutic medical equipment
Senseonics produces an implantable glucose sensor. How big is this industry? The chart below shows the overall market capitalization of the therapeutic devices sector. Its growth reflects the global diabetes epidemic and the technological race to create more convenient and accurate monitoring systems.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Senseonics chart is a visual representation of the battle for the continuous glucose monitoring market. The market capitalization of the company, which developed a long-lasting implantable sensor, reflects its efforts to compete with giants DexCom and Abbott. This diagram illustrates the difficulty of penetrating the market with an innovative but niche product.
Book value capitalization of the company, segment and market as a whole
SENS - Book value capitalization of the company Senseonics Holdings
For Senseonics, a developer of an implantable glucose monitoring sensor, its book value is its production lines and R&D labs. This is the physical foundation of its innovative medical technology. The chart below shows how the company has invested in its production and research capital.
SENS - Share of the company's book capitalization Senseonics Holdings within the market segment - Therapeutic medical equipment
Senseonics Holdings, Inc. creates implantable glucose monitoring systems. Its tangible assets are the production lines for its unique sensors and transmitters. These facilities are the physical foundation for a new era in diabetes treatment. The chart shows the company's control over this innovative medical manufacturing infrastructure.
Market segment balance sheet capitalization - Therapeutic medical equipment
Senseonics produces an implantable glucose meter. The medical device sector, as the chart shows, is capital-intensive. Senseonics is an innovator. Its business consists of R&D and factories that produce its unique, long-wear sensor.
Book value of all companies included in the broad market index - GURU.Markets
Senseonics's core business is its manufacturing capabilities for creating a unique implantable sensor for continuous glucose monitoring. The chart shows how the company expanded its production capabilities for this innovative system for diabetics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Senseonics Holdings
Senseonics owns manufacturing facilities. The market is paying a premium for their unique implantable glucose sensor. The chart shows how investor confidence in their ability to compete with giants like DexCom has changed.
Market to book capitalization ratio in a market segment - Therapeutic medical equipment
Senseonics Holdings produces an implantable continuous glucose monitoring system for diabetics. Its value lies in its unique technology. The chart shows how its market capitalization, based on product potential, compares to its current assets.
Market to book capitalization ratio for the market as a whole
Senseonics Holdings produces an implantable sensor for continuous glucose monitoring. Its valuation, unlike the average on this chart, is based on its unique technology, which offers a more convenient solution for people with diabetes. The market evaluates its potential to compete with market leaders, but with due consideration for commercial and production risks.
Debts of the company, segment and market as a whole
SENS - Company debts Senseonics Holdings
Senseonics Holdings produces an implantable sensor for continuous glucose monitoring. This chart illustrates the company's financial challenges in achieving widespread adoption of its product. Raising capital is necessary to finance commercial operations and compete with larger players in the diabetes device market.
Market segment debts - Therapeutic medical equipment
Senseonics Holdings developed and commercialized an implantable sensor for continuous glucose monitoring. This chart shows how its high debt load reflects its massive expenditures on R&D, clinical trials, and, most importantly, competing with market leaders like DexCom and Abbott for a share of the vast diabetes technology market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Senseonics Holdings
Senseonics Holdings produces an implantable continuous glucose monitoring system for people with diabetes. This chart shows the company's reliance on debt for production, marketing, and competition with larger market players. It is a key indicator of its financial strength as it seeks widespread adoption of its product.
Market segment debt to market segment book capitalization - Therapeutic medical equipment
Senseonics Holdings has developed an implantable sensor for continuous glucose monitoring. This chart shows the debt burden in the therapeutic medical device sector. It helps understand how the company is funding the commercialization of its innovative product and competing with other diabetes monitoring systems.
Debt to book value of all companies in the market
Senseonics Holdings produces implantable continuous glucose monitoring systems for people with diabetes. Competition in this market is fierce, requiring constant innovation and marketing efforts. This total market debt graph helps assess how the company finances its market share battle—through shareholders or through borrowing.
P/E of the company, segment and market as a whole
P/E - Senseonics Holdings
Senseonics Holdings developed and commercialized Eversense, the first and only implantable continuous glucose monitoring (CGM) system for people with diabetes. This chart shows how investors view its unique technology against market leaders Dexcom and Abbott. The pace of adoption is predicted.
P/E of the market segment - Therapeutic medical equipment
Senseonics Holdings developed and commercialized Eversense, the first and only implantable continuous glucose monitoring (CGM) system for people with diabetes that lasts up to six months. This chart shows the average rating for the therapeutic device sector, reflecting how the market values innovations that improve the quality of life for patients with chronic diseases.
P/E of the market as a whole
Senseonics Holdings develops and markets an implantable continuous glucose monitoring (CGM) sensor for diabetics. Its growth depends on its ability to compete with market leaders Dexcom and Abbott. Its business is driven by medical needs, not by general economic cycles, as reflected in this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Senseonics Holdings
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) sensor for people with diabetes that lasts up to six months. This graph reflects expectations for its unique technology. The company's valuation depends on its ability to compete with CGM market leaders such as Dexcom and Abbott.
%20P%2FE%20Senseonics%20Holdings&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Senseonics-Holdings&v=1772681730157 "Chart of the company's future (projected) P/E Senseonics Holdings")
Future (projected) P/E of the market segment - Therapeutic medical equipment
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) sensor for people with diabetes that can last up to six months. This chart reflects investors' views on its technology as it competes with market leaders. Comparing forecasts with the sector reveals whether investors believe it can capture a share of this large market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Therapeutic-medical-equipment&v=1772681730170 "Future (projected) P/E graph of the market segment - Therapeutic medical equipment")
Future (projected) P/E of the market as a whole
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) system for people with diabetes. It's an innovative product in a rapidly growing market. Against the backdrop of general market cycles, as illustrated by this chart, Senseonics's story is one of competing with market leaders and gaining acceptance of its technology by patients and doctors.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772681730182 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Senseonics Holdings
Senseonics Holdings, Inc. is a medical technology company that has developed an implantable continuous glucose monitoring (CGM) sensor for people with diabetes. The company's revenue depends on the adoption of its Eversense system by doctors and patients. This chart illustrates the complex path to commercialization of an innovative medical device.
Profit of companies in the market segment - Therapeutic medical equipment
Senseonics Holdings manufactures and markets an implantable sensor for continuous glucose monitoring in people with diabetes. The company offers a long-term solution compared to competitors. The profitability chart for the therapeutic medical device sector shows how rapidly the diabetes market is growing and how innovative products are vying for market share in this highly competitive environment.
Overall market profit
Senseonics Holdings has developed and commercialized an implantable continuous glucose monitoring (CGM) system for people with diabetes. Its Eversense product is a long-term alternative to traditional sensors. The company's growth depends on its ability to compete in the rapidly growing diabetes management market and reflects technological advances in this field.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Senseonics Holdings
Senseonics Holdings develops and markets an implantable continuous glucose monitoring (CGM) sensor for people with diabetes. This chart shows expectations for its ability to compete with market leaders like Dexcom. Revenue depends on user growth and distribution partnerships.
%20profit%20of%20the%20company%20Senseonics%20Holdings&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Senseonics-Holdings&v=1772681730227 "Graph of future (projected) profit of the company Senseonics Holdings")
Future (predicted) profit of companies in the market segment - Therapeutic medical equipment
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) system for people with diabetes. This chart shows forecasts for the medical device sector. It helps understand how the company's unique product competes with market leaders and its prospects in the growing CGM segment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Therapeutic-medical-equipment&v=1772681730235 "Graph of future (predicted) profits of companies in a market segment - Therapeutic medical equipment")
Future (predicted) profit of the market as a whole
This chart illustrates expectations for a company producing implantable continuous glucose monitoring systems for diabetics. Senseonics' profit forecast depends on the successful commercialization of its Eversense product. Competition from market leaders such as Dexcom and Abbott is fierce.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772681730236 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Senseonics Holdings
Senseonics Holdings produces an implantable sensor for continuous glucose monitoring. This chart shows how investors value its revenue in the competitive diabetes treatment market. The multiple reflects their belief in the advantages of its technology compared to competitors' products.
P/S market segment - Therapeutic medical equipment
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) system for people with diabetes. Revenue is driven by sales of the Eversense system. This chart shows the average market valuation, allowing one to assess how the market perceives Senseonics' unique technology and its ability to compete with non-implantable systems from industry giants.
P/S of the market as a whole
Senseonics Holdings has developed an implantable sensor for continuous glucose monitoring in people with diabetes, effective for up to six months. This differentiates the company from its competitors. This graph, showing the average revenue estimate for Senseonics, helps us understand how the market values its unique technology in the competitive environment of diabetes devices.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Senseonics Holdings
Senseonics Holdings has developed an implantable sensor for continuous glucose monitoring in people with diabetes. The company's future revenue depends on the successful commercialization of its Eversense system. This chart shows how investors assess its ability to compete with market leaders like DexCom and Abbott with its unique product.
%20P%2FS%20Senseonics%20Holdings&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Senseonics-Holdings&v=1772681730260 "The graph of the company's future (projected) P/S Senseonics Holdings")
Future (projected) P/S of the market segment - Therapeutic medical equipment
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) system for people with diabetes. This chart compares the company's estimated future sales with those of other therapeutic device manufacturers. It shows how investors view its unique product and its ability to compete with CGM market leaders.
%20P%2FS%20market%20segment%20graph%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Therapeutic-medical-equipment&v=1772681730271 "Future (projected) P/S market segment graph - Therapeutic medical equipment")
Future (projected) P/S of the market as a whole
Senseonics Holdings produces an implantable sensor for continuous glucose monitoring in people with diabetes. The company's growth depends on competition from market leaders and patient acceptance of its technology. Senseonics' success is an indicator of the development of the diabetes treatment device market, a huge and growing healthcare segment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772681730288 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Senseonics Holdings
Senseonics Holdings manufactures and markets an implantable continuous glucose monitoring (CGM) system for people with diabetes. This chart shows revenue from sales of its Eversense system, reflecting its competition in the rapidly growing CGM market and its ability to convince patients and doctors of its product's benefits.
Sales of companies in the market segment - Therapeutic medical equipment
Senseonics Holdings, Inc. developed and commercialized Eversense, the first and only continuous glucose monitoring (CGM) system with a sensor implanted under the skin for long periods (up to six months). This chart shows overall sales in the medical device market, illustrating how innovations in wearable technology are changing the lives of people with diabetes.
Overall market sales
Senseonics Holdings has developed and commercialized an implantable continuous glucose monitoring (CGM) system for people with diabetes. This economic outlook impacts Senseonics through healthcare costs. The growing number of people with diabetes creates a market, and economic health determines the ability of patients and insurers to pay for advanced technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Senseonics Holdings
Senseonics Holdings has developed an implantable sensor for continuous glucose monitoring in people with diabetes, effective for up to six months. This graph shows analysts' expectations for the long-term adoption of this monitoring system and its ability to compete with more traditional devices.
%20sales%20of%20the%20company%20Senseonics%20Holdings&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Senseonics-Holdings&v=1772681730302 "Schedule of future (projected) sales of the company Senseonics Holdings")
Future (projected) sales of companies in the market segment - Therapeutic medical equipment
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) system for people with diabetes. This chart shows projected revenue for the entire diabetes medical device sector. It reflects expected CGM market growth and competition among various glucose monitoring technologies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Therapeutic-medical-equipment&v=1772681730314 "Schedule of future (projected) sales of companies in the market segment - Therapeutic medical equipment")
Future (projected) sales of the market as a whole
Senseonics Holdings produces an implantable sensor for continuous glucose monitoring for people with diabetes. Demand for its product depends on competition and the willingness of insurance companies to cover its cost. This dynamic, reflecting the state of the economy, influences insurance policy. In a stable economic environment, they may be more willing to cover newer, more expensive technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772681730319 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Senseonics Holdings
Senseonics Holdings produces an implantable sensor for continuous glucose monitoring. This graph illustrates the challenges facing the medical company in a competitive environment. Profitability depends on the ability to grow market share while managing production costs and convincing patients and physicians of the benefits of its technology.
Market segment marginality - Therapeutic medical equipment
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) sensor for people with diabetes. This chart shows the company's operational structure as it competes with market leaders. It reflects its marketing and production expenditures as it seeks to gain a share of the rapidly growing diabetes treatment device market.
Market marginality as a whole
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) system for people with diabetes. The company's profitability depends on the adoption of its unique long-term system by patients and physicians. This total market return chart highlights how Senseonics is pursuing a niche in the rapidly growing diabetes management market with a differentiated product.
Employees in the company, segment and market as a whole
Number of employees in the company Senseonics Holdings
Senseonics Holdings has developed an implantable continuous glucose monitoring (CGM) sensor for people with diabetes. This chart shows the team working on commercializing this technology. The headcount dynamics reflect the partnership with a major company to promote the product and competition in the rapidly growing CGM market.
Share of the company's employees Senseonics Holdings within the market segment - Therapeutic medical equipment
This chart illustrates the innovative approach of Senseonics Holdings. The company's medical device division is focused on the development and sale of an implantable continuous glucose monitoring (CGM) system for people with diabetes. This team offers a long-term solution (up to six months) that eliminates the need for weekly sensor replacement.
Number of employees in the market segment - Therapeutic medical equipment
Senseonics Holdings manufactures and markets an implantable sensor for continuous glucose monitoring in people with diabetes. The long-term sensor improves patient convenience. This chart illustrates how medtech companies are creating innovative solutions for chronic disease management, creating demand for engineers and customer service specialists.
Number of employees in the market as a whole
Senseonics Holdings, Inc. produces implantable continuous glucose monitoring systems for diabetics. Its growth is driven by the rapid adoption of new technologies in medicine. This employment graph reflects an economy in which more and more people are gaining access to advanced medical devices through insurance.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Senseonics Holdings (SENS)
Senseonics Holdings has developed an implantable sensor for continuous glucose monitoring. This chart shows how the market values its innovative product. The high market capitalization per employee suggests that the company's value lies in its unique technology and patents, which can change the lives of people with diabetes, rather than in its scale.
%20of%20the%20company%20Senseonics%20Holdings%20(SENS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Senseonics-Holdings-SENS&v=1772681730423 "Chart of market capitalization per employee (in thousands of dollars) of the company Senseonics Holdings (SENS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
Senseonics Holdings produces an implantable continuous glucose monitoring (CGM) sensor for people with diabetes. This indicator reflects the market potential of its unique product. Comparisons with competitors help understand how investors view the advantages of the 90-day sensor compared to other CGM systems.
%20by%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Therapeutic-medical-equipment&v=1772681730434 "Market capitalization per employee (in thousands of dollars) by market segment - Therapeutic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Senseonics Holdings manufactures and markets an implantable sensor for continuous glucose monitoring for people with diabetes. This chart shows the market valuation of its unique technology. Its high cost per employee reflects the potential of its product to offer a more convenient alternative to traditional monitoring systems.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772681730441 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Senseonics Holdings (SENS)
Senseonics (SENS) is a medical technology company that produces the Eversense implantable glucose monitor (CGM), which lasts up to six months. It competes with Dexcom and Abbott. This chart shows the battle for market share. Revenue per employee depends on convincing patients and doctors of the benefits of their long-lasting system.
%20Chart%20Senseonics%20Holdings%20(SENS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Senseonics-Holdings-SENS&v=1772681730448 "Company Profit Per Employee (in thousands of dollars) Chart Senseonics Holdings (SENS)")
Profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
Senseonics Holdings produces Eversense, an implantable continuous glucose monitoring (CGM) sensor for diabetics that lasts up to six months. It directly competes with Dexcom and Abbott. This chart shows how effectively the company is selling its innovative, yet niche, system. It serves as a benchmark for assessing Senseonics' success in this CGM technology race.
%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Therapeutic-medical-equipment&v=1772681730458 "Chart of profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Senseonics (SENS) produces and sells the Eversense implantable continuous glucose monitoring (CGM) sensor for people with diabetes. It's a competitive medical device market. This graph (loss-making) shows their battle for market share. Their product is innovative (a 6-month implant) but requires surgery. They spend heavily on R&D and sales to convince doctors and patients.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772681730459 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Senseonics Holdings (SENS)
Senseonics Holdings has developed an implantable sensor for continuous glucose monitoring. This chart shows how the company competes in the rapidly growing diabetes treatment market. Growth in revenue per employee will depend on the adoption of its technology by patients and doctors.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Senseonics-Holdings-SENS&v=1772681730462 "Sales chart per company employee Senseonics Holdings (SENS)")
Sales per employee in the market segment - Therapeutic medical equipment
Senseonics Holdings produces an implantable continuous glucose monitoring system (Eversense) for people with diabetes. This chart shows the average revenue per employee in the segment. It demonstrates how productive their team is in promoting this unique technology compared to market leaders (Dexcom, Abbott).
Sales per employee for the market as a whole
Senseonics is a company that produces an implantable continuous glucose monitoring (CGM) sensor for diabetics (brand name Eversense). They compete with Dexcom. This chart shows how successfully their team (R&D, sales) is promoting their innovative, yet lesser-known, product in the highly competitive CGM market.
Short shares by company, segment and market as a whole
Shares shorted by company Senseonics Holdings (SENS)
Senseonics (SENS) is a manufacturer of implantable continuous glucose monitoring (CGM) sensors for diabetics. The bearish sentiment seen on this chart reflects fierce competition. Bears are betting that SENS will be unable to compete with CGM market giants DexCom and Abbott (Freestyle Libre).
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Senseonics-Holdings-SENS&v=1772681730505 "Short Shares Chart for the Company Senseonics Holdings (SENS)")
Shares shorted by market segment - Therapeutic medical equipment
Senseonics Holdings produces an implantable continuous glucose monitoring (CGM) sensor for diabetics that lasts up to six months. This chart shows the overall sentiment in the sector. It reflects investor concerns about fierce competition from market leaders (Dexcom, Abbott) and the challenges of implementing implantable systems.
Shares shorted by the overall market
Senseonics (SENS) produces an implantable sensor for continuous glucose monitoring. The company competes with giants like DexCom and Abbott. This chart measures risk appetite. When fear dominates, investors doubt the ability of "David" (SENS) to defeat "Goliath" companies and sell off the stocks of underdogs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Senseonics Holdings (SENS)
Senseonics develops implantable continuous glucose monitoring (CGM) systems. Success depends on technology adoption and reimbursement. This chart can soar above 70 on positive FDA news, accuracy data, or partnerships. A range below 30 often reflects concerns about competition, reimbursement issues, or slow adoption.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Senseonics-Holdings-SENS&v=1772681730522 "RSI 14 indicator chart for the company's stock Senseonics Holdings (SENS)")
RSI 14 Market Segment - Therapeutic medical equipment
Senseonics (SENS) is a rebel in the diabetes world. While DexCom and Abbott are making patches, SENS is creating the Eversense implantable glucose sensor (180 days). The RSI_14_Seg for their segment (medtech) shows whether the entire CGM (glucose monitoring) sector is overbought. This helps us understand: is SENS's growth driven by their technology or by general hype?
RSI 14 for the overall market
Senseonics (SENS), a manufacturer of implantable glucose sensors, sees this chart as a sign of a willingness to innovate. In times of euphoria, investors and insurers are willing to finance new, expensive medical technology solutions. In times of panic, the focus shifts to cost savings, and patients and doctors may prefer older, cheaper monitoring methods, slowing SENS adoption.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SENS (Senseonics Holdings)
Senseonics (SENS) produces the Eversense implantable continuous glucose monitoring (CGM) sensor, which lasts up to 180 days. This chart shows the average 12-month forecast. It reflects analysts' expectations for the company's ability to compete with market leaders (Dexcom, Abbott) and convince patients of the implant's convenience.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SENS-Senseonics-Holdings&v=1772681730549 "A chart showing analyst consensus forecasts for the expected stock price. SENS (Senseonics Holdings)")
The difference between the consensus estimate and the actual stock price SENS (Senseonics Holdings)
Senseonics (SENS) is a medical technology company that competes with DexCom. It produces Eversense, a unique glucose monitoring system (CGM) that is implanted under the skin for six months. This chart shows the difference between the consensus estimate and the price, reflecting analyst confidence in this niche CGM technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SENS-Senseonics-Holdings&v=1772681730567 "A chart showing the difference between the consensus forecast and the actual stock price. SENS (Senseonics Holdings)")
Analyst consensus forecast for stock prices by market segment - Therapeutic medical equipment
Senseonics (SENS) is a medical device company that developed Eversense, the first implantable continuous glucose monitor (CGM) for diabetics that lasts up to six months. This chart shows general expectations for the therapeutic medical device sector. It reflects whether experts believe this technology will compete with DexCom and Abbott.
Analysts' consensus forecast for the overall market share price
Senseonics is the company that produces Eversense, an implantable (inserted under the skin) continuous glucose monitoring (CGM) sensor that lasts for six months. This chart shows overall market sentiment. For Senseonics, which competes with giants like DexCom and Abbott, it's important to understand how these expectations (risk appetite) impact their battle for market share. (345)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Senseonics Holdings
Senseonics is a medtech company operating in the diabetes market. They produce Eversense, an implantable (inserted under the skin) continuous glucose monitoring (CGM) sensor with a long lifespan (6 months). This chart is a barometer of their adoption. It likely reflects their ability to compete with non-invasive leaders (Dexcom, Abbott) and convince patients of the benefits of their implant.
AKIMA Market Segment Index - Therapeutic medical equipment
Senseonics (SENS) is a medtech innovator in diabetes; the company (a competitor of DexCom) produces Eversense, the first (and only) fully implantable continuous glucose monitoring (CGM) sensor with a six-month lifespan. This aggregate metric evaluates companies. The graph shows the sector average. This benchmark: how does this unique (implant) technology (SENS) differentiate it from the average competitor?
The AKIM Index for the overall market
Senseonics is a developer of implantable continuous glucose monitoring systems (Eversense) for diabetics. This chart, reflecting the market average, is a backdrop. It helps assess how this innovative but niche MedTech company, competing with giants, stacks up against overall macroeconomic trends.
